Talk to us a little bit about which ones those are.

You betcha.

Uh, acute lymphoblastic leukemia in children and in adults, the standard of care for a relapsed, refractory, not responding to treatment, or even relapsing after a stem cell transplant, uh, represents the standard of care in the United States now with a overall response rate of, uh, greater than 90% in those patients as a curative therapy for those patients.

Non-Hodgkin's lymphomas, a broad array of B-cell non-Hodgkin's lymphomas, the most common forms of non-Hodgkin's lymphoma in the United States, are eligible for CAR T-cell therapy.

Ag- uh, and then finally, multiple myeloma, which Dr. Abdulla will speak to a little bit more, that's moved up in our armamentarium.

Uh, and just two points to, uh, to the, uh, issue of, uh, access, uh, and the issue of moving things up front.

We've shown in a publication from our center that the further patients live from the center, the less likely it is that they're going to be able to access a CAR T-cell, uh, therapy.

Dr. McGuirt.